Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

June 15, 2022

Study Completion Date

September 15, 2022

Conditions
Post-COVID-19 SyndromeLung Fibrosis
Interventions
DRUG

Corticosteroids alone

(≥ 20 mg prednisolone or its equivalent for ≥ 10 days after hospital discharge)

DRUG

Corticosteroids + Colchicine

(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Colchicine (1 mg/day for ≥ 10 days)

DRUG

Corticosteroids + Pirfenidone

(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Pirfenidone (267 mg TID for ≥ 14 days)

DRUG

Corticosteroids + Colchicine + Pirfenidone for ≥ 14 days

(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Colchicine (1 mg/day for ≥ 10 days) + Pirfenidone (267 mg TID for ≥ 14 days)

Trial Locations (1)

35511

Mansoura University, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT05648734 - Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter